原发性醛固酮增多症 中国就医指南

Primary aldosteronism (PA), also known as Conn’s syndrome, is a common and potentially curable form of secondary hypertension caused by autonomous overproduction of aldosterone from the adrenal glands—most frequently due to an aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). Unlike physiological aldosterone secretion—which is tightly regulated by the renin-angiotensin system and potassium levels—PA involves dysregulated, excessive mineralocorticoid activity. This leads to sodium retention, potassium wasting, plasma volume expansion, and suppression of plasma renin activity. The resulting chronic hypertension is often resistant to conventional antihypertensive therapy and carries significantly higher cardiovascular morbidity and mortality compared to essential hypertension, including increased risks of left ventricular hypertrophy, atrial fibrillation, stroke, and chronic kidney disease. Epidemiologically, PA affects approximately 5–10% of all patients with hypertension, rising to 15–20% among those with resistant hypertension (defined as uncontrolled BP despite ≥3 antihypertensives, including a diuretic). It is underdiagnosed globally; screening is recommended for patients with early-onset hypertension (<40 years), spontaneous or diuretic-induced hypokalemia, adrenal incidentaloma, family history of PA or early-onset stroke, or hypertension with sleep apnea. Key risk factors include obesity, metabolic syndrome, advancing age (peak incidence 30–50 years), and genetic predispositions such as germline mutations in KCNJ5, CACNA1D, or ATP1A1—though most cases are sporadic. Importantly, PA is not rare in normotensive individuals with unexplained hypokalemia or recurrent nephrolithiasis. Quality of life is substantially impaired: patients commonly report fatigue, muscle weakness, nocturia, headaches, palpitations, and cognitive fog—symptoms often misattributed to stress or aging. Untreated PA accelerates end-organ damage and increases healthcare utilization. Early diagnosis via plasma aldosterone-to-renin ratio (ARR) followed by confirmatory testing (e.g., saline infusion test or oral sodium loading) and adrenal imaging (CT/MRI) enables targeted management—either surgical adrenalectomy for unilateral disease or mineralocorticoid receptor antagonists (e.g., spironolactone or eplerenone) for bilateral or non-surgical cases. With appropriate intervention, blood pressure control improves markedly, potassium normalizes, and cardiovascular risk declines significantly. Patient education, long-term monitoring of electrolytes and renal function, and multidisciplinary care involving endocrinologists, hypertension specialists, and adrenal surgeons are critical to optimizing outcomes.

# 原发性醛固酮增多症治疗方案与费用明细（内分泌科）

一、非手术/药物治疗方案

适用人群：双侧肾上腺增生型、无法手术者、术前准备或术后残留高血压者。

• •一线药物：螺内酯（40–200 mg/d）或依普利酮（50–200 mg/d）
• •检查费（初筛+随访）：血浆醛固酮/肾素活性比（ARR）、卧立位试验、肾上腺CT（平扫+增强）、24h尿钾/钠、电解质、肾功能——¥1,800–¥3,200/次
• •年药费：国产螺内酯 ¥120–¥360；依普利酮（原研）¥3,600–¥7,200；含门诊随访（每3月1次）总年支出 ¥2,500–¥9,000

二、手术治疗方案

适用人群：单侧醛固酮瘤（经AVS确诊为优势侧分泌）、影像学明确单侧结节（≥4 cm或PET阳性）。

• •术式：腹腔镜肾上腺切除术（金标准）
• •术前检查：肾上腺静脉采血（AVS，核心确诊手段）¥8,000–¥12,000；CT/MRI ¥1,200–¥2,500
• •手术总费用（含住院7–10天、麻醉、病理、护理）：¥32,000–¥48,000（三甲医院医保报销后自付约¥10,000–¥18,000）

三、特殊复杂情况处理

• •AVS失败/双侧分泌/耐药型：联合螺内酯+钙通道阻滞剂+低钠饮食；年管理成本 ¥4,000–¥12,000
• •合并难治性低钾心律失常或肾功能恶化：需ICU监护、静脉补钾及RAAS抑制剂调整，单次住院 ¥15,000–¥35,000

四、方案快速选择指南

• •预算有限/老年/双侧增生 → 首选螺内酯+规律随访（年均¥3,000内）
• •年轻患者/单侧瘤/血压难控 → 积极行AVS评估，择期腹腔镜手术（根治率>90%）
• •AVS禁忌/高龄/多病共存 → 依普利酮替代+心肾专科协同管理